Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Dimerix Quarterly Activities Report and Appendix 4C 10 pages 600.1KB
Regulatory Filings
2026-04-29 English
ACTION3 Statistical Review Complete 4 pages 440.7KB
Regulatory Filings
2026-04-27 English
Dimerix Releases Investor Presentation and Video Recording 26 pages 3.5MB
Regulatory Filings
2026-04-27 English
Dimerix Singapore Investor Briefing 2 pages 346.1KB
Regulatory Filings
2026-04-08 English
Dimerix to Conduct Review of ACTION3 Statistical Assumptions 3 pages 390.7KB
Regulatory Filings
2026-03-15 English
Dimerix Presents at Euroz Hartleys Institutional Conference 28 pages 3.8MB
Regulatory Filings
2026-03-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.